Framing the argument over futile care
This editorial argues that handling the transition from active to palliative care is indeed a weak point in oncology, and if the cancer community fails to address it, we will leave it open to the [more]
Number 48
This editorial argues that handling the transition from active to palliative care is indeed a weak point in oncology, and if the cancer community fails to address it, we will leave it open to the accountants to set the agenda on..... [ more ]
Mahasti Saghatchian: pioneering a quality mark for Europe’s cancer centres
She’s an internationalist, she believes in quality control and she’s not afraid of a bit of friction. Who better, then, to lead the project to define standards for Europe’s cancer centres and sort the centres [more]
Recent trials in osteosarcoma and their implications for future studies
In this overview a sarcoma specialist present current evidence on the best way to manage osteosarcoma patients and looks at what has to be done to improve prognosis in this disease, where survival rates have [more]
Can the Reverend Bayes help deliver proven therapies for patients with rare cancers?
Conducting clinical trials in people with rare cancers is not easy when the number in a small trial do not add up to convincing evidence. Now some researchers are pressing for a new approach–using Bayesian [more]
Fixing the holes in the opioid supply lines
Patients are still dying in agony despite concerned efforts over many years to change attitudes towards the use and control of opiates. Could a new initiative, which works with NGOs, governments and policy makers to [more]
Prostate cancer units: it’s about options and quality
Men diagnosed with prostate cancer have a wealth of options on how to proceed, but they can pay a high price if the quality of treatment is substandard. Could delivering all prostate care through specialist [more]
Localised non-bulky Hodgkin lymphoma – future questions
Late toxicities from radiation therapy are frequent in patients with Hodgkin lymphoma and can hamper survival. These late toxicities should decrease with modern radiation therapy, but results are not mature and so the importance of [more]
First-line bevacizumab for ovarian cancer – new standard of care?
Demonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab [more]
Newsround
Complications from robotic prostatectomy no better than conventional surgery ‹ Journal of Clinical Oncology Problems with continence and sexual function are common following both robot-assisted laparoscopic radical prostatectomy (RALRP) and open retropubic radical prostatec-tomy (ORRP), [more]